会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 7. 发明授权
    • Imidazotriazinone derivatives as PDE 7 (phosphodiesterase 7) inhibitors
    • 咪唑并三嗪酮衍生物作为PDE 7(磷酸二酯酶7)抑制剂
    • US07713972B2
    • 2010-05-11
    • US10560503
    • 2004-06-11
    • Hidekazu InoueHidenobu MurafujiYasuhiro Hayashi
    • Hidekazu InoueHidenobu MurafujiYasuhiro Hayashi
    • A61K31/53A01N43/64A01N43/66C07D253/08C07D487/00
    • C07D487/04
    • The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotriazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.
    • 本发明提供了选择性抑制PDE7的化合物,因此增强细胞cAMP水平。 因此,该化合物可用于治疗各种疾病如过敏性疾病,炎性疾病或免疫疾病。 该化合物是由下式(IA)或(IB)表示的咪唑并三氮酮化合物:特别是R 1是环己基,R 2是甲基; R3是氢原子; 硝基; 氰基; 卤素原子; 杂芳基; 取代或未取代的C 1 -C 6烷基; 取代或未取代的C 2 -C 6烯基; 取代或未取代的饱和或不饱和杂环烷基; 基团:-NR5R6,-C(O)R7,-SO2R7,-OR8,-NR8COR7,-NR8S02R7; A是CR4; 而B是CH。
    • 9. 发明申请
    • Imidazotriazinone derivatives as pde 7 (phosphodiesterase 7) inhibitors
    • 咪唑三嗪酮衍生物作为pde 7(磷酸二酯酶7)抑制剂
    • US20060128707A1
    • 2006-06-15
    • US10560503
    • 2004-06-11
    • Hidekazu InoueHidenobu MurafujiYasuhiro Hayashi
    • Hidekazu InoueHidenobu MurafujiYasuhiro Hayashi
    • A61K31/53C07D487/04
    • C07D487/04
    • The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotirazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.
    • 本发明提供了选择性抑制PDE7的化合物,因此增强细胞cAMP水平。 因此,该化合物可用于治疗各种疾病如过敏性疾病,炎性疾病或免疫疾病。 该化合物是由下式(IA)或(IB)表示的咪唑并嗪酮化合物:特别是R 1是环己基,R 2是甲基; R3是氢原子; 硝基; 氰基; 卤素原子; 杂芳基; 取代或未取代的C 1 -C 6烷基; 取代或未取代的C 2 -C 6烯基; 取代或未取代的饱和或不饱和杂环烷基; 基团:-NR5R6,-C(O)R7,-SO2R7,-OR8,-NR8COR7,-NR8S02R7; A是CR4; 而B是CH。